

# Thrombocytopenia (short version)

Recommendations from the society for diagnosis and therapy of  
haematological and oncological diseases

## **Publisher**

DGHO Deutsche Gesellschaft für Hämatologie und  
Medizinische Onkologie e.V.  
Bauhofstr. 12  
D-10117 Berlin

Executive chairwoman: Prof. Dr. med. Claudia Baldus

Phone: +49 (0)30 27 87 60 89 - 0

[info@dgho.de](mailto:info@dgho.de)

[www.dgho.de](http://www.dgho.de)

## **Contact person**

Prof. Dr. med. Bernhard Wörmann  
Medical superintendent

## **Source**

[www.onkopedia-guidelines.info](http://www.onkopedia-guidelines.info)

The information of the DGHO Onkopedia Web Site is not intended or implied to be a substitute for professional medical advice or medical care. The advice of a medical professional should always be sought prior to commencing any form of medical treatment. To this end, all component information contained within the web site is done so for solely educational purposes. DGHO Deutsche Gesellschaft für Hämatologie und Onkologie and all of its staff, agents and members disclaim any and all warranties and representations with regards to the information contained on the DGHO Web Site. This includes any implied warranties and conditions that may be derived from the aforementioned web site information.

# Table of contents

<b>1 Summary</b> .....	<b>2</b>
<b>2 Therapy</b> .....	<b>2</b>
<b>15 Authors' Affiliations</b> .....	<b>3</b>
<b>16 Disclosures</b> .....	<b>4</b>

# Thrombocytopenia (short version)

**ICD-10:** D69.4

**Date of document:** March 2021

## **Compliance rules:**

- [Guideline](#)
- [Conflict of interests](#)

**Authors:** Karl-Anton Kreuzer, Norbert Gattermann, Johanna Gebhart, Jeroen Goede, Martin Griebhammer, Edgar Jost, Florian Langer


## **1 Summary**

A deficiency of platelets results from a reduced production in the bone marrow (formation disorder) or from an increased loss (consumption disorder). The patient's risk is largely determined by the extent of thrombocytopenia (platelet count), its duration, the respective disease etiology, and other patient-specific factors (e.g., age-related vascular fragility, comorbidity, or anti-coagulant medication). For prognosis, a rapid diagnosis with recording of the pathogenesis is crucial, as effective treatments are available for most thrombocytopenias, which can significantly reduce the morbidity and mortality of thrombocytopenia and/or its underlying systemic disease.

## **2 Therapy**

The current treatment algorithm is depicted in [Figure 1](#).

**Figure 1: Diagnostic algorithm for thrombocytopenia**



## 15 Authors' Affiliations

**Prof. Dr. med. Norbert Gattermann**

**apl. Prof. PD Dr. med. Johanna Gebhart**

Medizinische Universität Wien

Universitätsklinik für Innere Medizin

Abteilung für Hämatologie und Hämostaseologie

Währinger Gürtel 18-20

A-1090 Wien

[johanna.gebhart@meduniwien.ac.at](mailto:johanna.gebhart@meduniwien.ac.at)

**PD Dr.med. Jeroen Goede**

Medizinische Onkologie und Hämatologie

Kantonsspital Winterthur

Brauerstr. 15

CH-8401 Winterthur

[jeroen.goede@ksw.ch](mailto:jeroen.goede@ksw.ch)

**Prof. Dr. med. Martin Griebshammer**

Johannes Wesling Klinikum Minden

Klinik für Hämatologie / Onkologie

Hans-Nolte-Str. 1

32429 Minden

[martin.griesshammer@muehlenkreiskliniken.de](mailto:martin.griesshammer@muehlenkreiskliniken.de)

**Prof. Dr. med. Edgar Jost**

Uniklinik RWTH Aachen  
Medizinische Klinik IV  
Pauwelsstr. 30  
52074 Aachen  
[ejost@ukaachen.de](mailto:ejost@ukaachen.de)

**Prof. Dr. med. Karl-Anton Kreuzer**

Klinikum der Universität zu Köln  
Klink I für Innere Medizin  
Kerpener Str. 62  
50937 Köln  
[karl-anton.kreuzer@uk-koeln.de](mailto:karl-anton.kreuzer@uk-koeln.de)

**Prof. Dr. med. Florian Langer**

Universitätsklinikum Hamburg-Eppendorf  
Med. Klinik II  
Abteilung Hämatologie/Onkologie  
Martinistr. 52  
20246 Hamburg  
[langere@uke.de](mailto:langere@uke.de)

## **16 Disclosures**

Conflicts of interest can be found in the [full German version of the guideline](#).